MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents and net cash burn during the first quarter of 2022 should have been stated as €20.5 million ($22.9 million) and €9.5 million ($10.6 million), respectively, not €20.6 million ($23.0 million) and €9.4 million ($10.5 million), respectively. The corrected release follows:
Read more at globenewswire.comCORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
/Super%20Micro%20Computer%20Inc%20HQ%20photo-by%20Tada%20Images%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_billboard-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
